Early postoperative intraperitoneal chemotherapy for lower gastrointestinal neoplasms with peritoneal metastasis: a systematic review and critical analysis
Open Access
- 1 September 2019
- journal article
- review article
- Published by Walter de Gruyter GmbH in Pleura and Peritoneum
- Vol. 4 (3) , 20190007
Abstract
Background: Early postoperative intraperitoneal chemotherapy (EPIC) can be used in combination with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat patients with peritoneal carcinomatosis (PC) of multiple origins. The present study is a systematic review to evaluate the role of EPIC after CRS + HIPEC for appendiceal and colorectal cancers with PC. Content: We conducted a systematic search in PubMed according to the PRISMA guidelines and included all studies published before June 27 of 2019 comparing EPIC to HIPEC or the combination of both. Our search found 79 articles. After excluding non-relevant articles, a total of 13 retrospective clinical studies reporting on the efficacy and safety of EPIC compared to HIPEC or as a combination therapy for lower gastrointestinal neoplasms were analyzed. Initial EPIC reports led to its declined usage because of concerns with increased postoperative morbidity and uncertain added benefit on survival. Recent retrospective studies have been promising, showing significant improvements in OS and fewer issues with complications when adding EPIC to CRS + HIPEC. Conclusions: Current evidence is entirely retrospective and is conflicting. It is hoped that ongoing clinical trials and additional studies will clarify EPIC’s role in the treatment of patients with PC.Keywords
This publication has 44 references indexed in Scilit:
- Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal ChemotherapyJournal of Clinical Oncology, 2012
- Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy PatientsGastroenterology Research and Practice, 2012
- Results of Two Bi-Institutional Prospective Studies Using Intraperitoneal Oxaliplatin With or Without Irinotecan During HIPEC After Cytoreductive Surgery for Colorectal CarcinomatosisAnnals of Surgery, 2011
- Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case–control studyAnnals of Oncology, 2011
- Which Method to Deliver Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin? An Experimental Comparison of Open and Closed TechniquesAnnals of Surgical Oncology, 2010
- Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French StudyJournal of Clinical Oncology, 2010
- Pharmacokinetics and Pharmacodynamics of Perioperative Cancer Chemotherapy in Peritoneal Surface MalignancyThe Cancer Journal, 2009
- Comparison of Two Kinds of Intraperitoneal Chemotherapy Following Complete Cytoreductive Surgery of Colorectal Peritoneal CarcinomatosisAnnals of Surgical Oncology, 2006
- SURGICAL ONCOLOGY AND THE ROLE OF REGIONAL CHEMOTHERAPYAnz Journal of Surgery, 1992
- Gastrointestinal malignancy: Rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapyBritish Journal of Surgery, 1989